Lonza buys Merck CDMO in Germany to double U.S. footprint as Korea rivals race
Lonza, the world's top biopharmaceutical CDMO, will acquire Merck KGaA's U.S. CDMO business for 100-600 million Swiss francs, adding five sites and 1,100 employees. The deal, expected to close in mid-2027, will expand Lonza's U.S. production bases from four to nine. Merck plans to focus on other innovative businesses. Samsung Biologics and Celltrion are also expanding U.S. production capacities.
How this was made
The 30-second read
Why it matters
For Lonza, the acquisition increases U.S. CDMO bases from four to nine and adds specialized production for ADCs, viral vectors, and LNP delivery, with projected 2028 sales of about 250 million Swiss francs. For Merck, the sale is not a full exit, as it plans to continue supplying consumables, technologies, and services.
Market read
This is a concrete cross-border CDMO deal that changes U.S. capacity ownership and competitive positioning, with deal-close timing into mid-2027 and a 2028 sales projection for the acquired business.
What to watch
Regulatory approval timing and integration of highly specialized modalities (ADCs, viral vectors, LNP) could delay ramp-up; Biosecure Act effects may benefit some regions but also re-route client qualification timelines.
Background
Merck is reshuffling its Life Science portfolio by selling its CDMO business to Lonza, while the article frames broader CDMO capacity competition among global and Korean players amid Biosecure Act constraints on certain Chinese biotech suppliers.
Ticker impact
Merck KGaA agreed to sell its Life Science division CDMO business to Lonza, including five U.S. production facilities, as part of a portfolio reshuffle.
Likely neutral to mildly negative near-term as investors assess earnings mix and execution risk, offset by capital redeployment and strategic focus.
The article discloses the divestment scope and strategic rationale but does not provide transaction value, limiting precision on financial impact.
Market effects
Reinforces consolidation and capacity build in biopharma CDMO, potentially intensifying competition for ADCs, viral vectors, and LNP delivery services.
U.S. CDMO capacity shifts toward Lonza as five U.S. sites move under its control, while Korea-based rivals are portrayed as expanding overseas footprint.
Highlights how national security procurement rules (Biosecure Act) may reshape CDMO sourcing and shift demand toward non-targeted regions.
Counterpoint
The deal’s financial impact is uncertain because the transaction value is undisclosed; capacity gains may not translate into near-term margin improvement if utilization lags.
Key entities
- companyLonza
Acquirer of Merck KGaA’s Life Science CDMO business, adding five U.S. production sites and expanding U.S. footprint.
- companyMerck KGaA
Seller of its Life Science division CDMO business to Lonza as part of a portfolio reshuffle.
- companySamsung Biologics
Korean CDMO player referenced for ongoing overseas capacity expansion and related acquisition activity.
- companyCelltrion
Korean biotech referenced for prior acquisition of a U.S. plant and expansion of contract manufacturing.
- lawBiosecure Act
U.S. procurement restriction targeting equipment/services contracting with biotech corporations of concern, cited as a potential industry landscape changer.
